Metabolomics and Pharmacometabolomics: Advancing Precision Medicine in Drug Discovery and Development
Metabolites · 18.11.2025 · 15 (11) · 750
DOI: 10.3390/metabo15110750 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 18.11.2025. Verfasst von Eleni V Stolaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolomics and pharmacometabolomics are at the forefront of precision medicine, serving as powerful tools in drug discovery and development. These approaches help address critical challenges in the field, including high clinical trial failure rates, adverse drug reactions, and interindividual variability in drug response. Comprehensive metabolome profiling enables the elucidation of disease mechanisms, identification of drug targets, optimization of therapeutic strategies, and assessment of drug safety and efficacy. It also supports more informed clinical trial design. This review highlights the pivotal role of metabolomics in advancing precision medicine and aims to broaden the perspectives of emerging scientists entering this complex field. Key analytical techniques–namely mass spectrometry and nuclear magnetic resonance spectroscopy–are discussed for their respective strengths and limitations in metabolite identification, quantitation, and structural elucidation. Additionally, analytical separation technologies such as liquid and gas chromatography, ion mobility spectrometry, capillary electrophoresis, and supercritical fluid chromatography are explored for their potential to enhance metabolome coverage, improve analytical efficiency, and reduce costs. Ongoing advancements in instrumentation and computational tools are helping to overcome major challenges in metabolomics, including metabolome complexity, data analysis and integration, and biomarker validation. These developments continue to expand the applications of metabolomics and pharmacometabolomics in both preclinical and clinical research. Ultimately, this review underscores their translational potential in facilitating drug discovery, mitigating risks in clinical trials, and shaping the future of precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece.
- Functional Proteomics and Systems Biology (FunPATh)-Center for Interdisciplinary Research and Innovation (CIRI-AUTH), GR-57001 Thessaloniki, Greece.
- Laboratory of Medical Biology-Medical Genetics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece.
- Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece.
ORCID-Profile: Michalis Aivaliotis
Zitieren
APA
Stolaki, E. V., Psatha, K., & Aivaliotis, M. (2025). Metabolomics and Pharmacometabolomics: Advancing Precision Medicine in Drug Discovery and Development. Metabolites, 15(11), 750. https://doi.org/10.3390/metabo15110750
Vancouver
Stolaki EV, Psatha K, Aivaliotis M. Metabolomics and Pharmacometabolomics: Advancing Precision Medicine in Drug Discovery and Development. Metabolites. 2025;15(11):750. doi:10.3390/metabo15110750
BibTeX
@article{Stolaki2025,
author = {Stolaki, Eleni V and Psatha, Konstantina and Aivaliotis, Michalis},
title = {Metabolomics and Pharmacometabolomics: Advancing Precision Medicine in Drug Discovery and Development},
journal = {Metabolites},
year = {2025},
volume = {15},
number = {11},
pages = {750},
doi = {10.3390/metabo15110750}
}
EUVIMED